Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine effective dose study for suppressing movement during pediatric caudal block
ChiCTR2300070462Phase 4Not yet recruiting
- Sponsor
- Xuzhou Children's Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine in None (5 arms), sponsored by Xuzhou Children's Hospital. Primary endpoint: Successful sacral block. Planned start May 2023; status: not yet recruiting.
02
Drugs
esketamine
Beyond the preview
Go deeper on ChiCTR2300070462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070462.